Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
A1 A2 A3
KVUE
FY2025 Q2
Понижен
Отчётный звонок Kenvue Inc.
Вывод Buzzberg
Revised 2025 guidance to low single-digit organic sales decline
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
Вывод Buzzberg Revised 2025 guidance to low single-digit organic sales decline Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05. Читать полный анализСвернуть анализ
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
- Reported Q2 2025 organic sales declined 4.2% year-over-year, massively underperforming consumption growth, driven by retailer inventory destocking.
- Identified a 83% of US self-care business held or gained share, with Tylenol and Zyrtec as bright spots despite weak seasons.
- Admitted to self-induced complexity with 115 brands and a long tail of SKUs accounting for ~1% of sales.
Выручка$3.839B+3% к/к
EPS$0.29+21% к/к
Валовая маржа58.9%Факт
Операционная маржа18.03%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Strategy
Plan to reduce complexity by trimming SKU tail
Leadership
New leaders appointed to one-third of leadership team
Показать ещё 3 тезиса
Strategy
Strategic review of alternatives underway with board committee
Costs
Tariffs expected to have $150 million annualized impact
Performance
Q2 organic sales declined 4.2%, below expectations
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $3.839B | +3% к/к |
| EPS | $0.29 | +21% к/к |
| Валовая маржа | 58.9% | Факт |
| Операционная маржа | 18.03% | Факт |
| Свободный денежный поток | $0.533B | Факт |
| Капзатраты | $0.088B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2025 | $1.00–$1.05 | $1.02 | Понижен |
| Выручка | FY2025 | -3%–-1% | -2% | Понижен |
AI, капзатраты и спрос
Оценка менеджмента
Cautiously Determine
Management acknowledged weak results and challenges, but expressed confidence in executing a turnaround through focused priorities and leadership changes.
Оценка AI от менеджмента
Management emphasized leveraging data and AI capabilities as part of a modern CPG playbook, and announced a new Chief Technology and Data Officer to accelerate digital and AI capabilities.
все упомянутые компании ниже: 5
Компаниис момента звонка
Цепочка поставок
Цепочка поставок
Amit Banati
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility. — The consumption-to-shipment gap indicates a channel-wide inventory correction, which could signal a temporary headwind for competitors relying on shipments to retailers for their own reported sales.
Доказательства
“global consumption grew year over year and outpaced organic sales across each segment.”
Цепочка поставок
Kirk Perry
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands. — Zyrtec's share and penetration gains during a weak tide indicate it is taking share from competitors, signaling a negative trend for competing allergy franchises in the US.
Доказательства
“Zyrtec didn't just strengthen its leadership position, but also grew household penetration across both adult and children franchises.”
Цепочка поставок
Amit Banati
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment. — This admission provides a clear roadmap for competitors to double down on the alcohol-free oral care segment to entrench their share gains against Listerine.
Доказательства
“The key challenge our teams are addressing is on our portfolio mix where we are not playing strongly enough in the fastest growing mild alcohol free segment.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility.
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands.
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 5. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.